Overview
AUTL market data
Price History
AUTL price chart · 1M
- O
- 1.78
- H
- 1.78
- L
- 1.74
- C
- 1.74
- Vol
- 23,348.00
Daily history from Jun 22, 2018
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $1.78
- Previous Close
- $1.80
- Day High
- $1.78
- Day Low
- $1.74
- 52 Week High
- $2.58
- 52 Week Low
- $1.18
- 7 Day Return
- -5.95%
- 30 Day Return
- -17.34%
- 90 Day Return
- +7.41%
- 1 Year Return
- -0.85%
- Daily Notional Volume
- $40.6K Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.08 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.36 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -238.7% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.18 – $2.58 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $487.1M · P/B 2.94 · P/S 4.15.
Company News
10 captured
Autolus Therapeutics Published Abstract Filed TO American College Of Rheumatology Convergence 2026Benzinga ·
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient DemandGlobenewswire Inc ·
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient AccessGlobenewswire Inc ·
Lupus Nephritis Market on a Growth Trajectory at a CAGR of 7% During the Forecast Period (2026–2036), as Innovative Therapies Gain Momentum | DelveInsightGlobenewswire Inc ·
8-K filing — Autolus Therapeutics plc (AUTL)SEC EDGAR ·
Autolus Therapeutics Affirms FY2026 Sales Guidance of $140.000M-$150.000M vs $136.669M EstBenzinga ·